Your browser doesn't support javascript.
loading
Clinical characteristics of primary extranodal versus nodal diffuse large B-Cell Lymphoma: A retrospective cohort study in a cancer center
Candelaria, Myrna; Oñate-Ocaña, Luis F.; Corona-Herrera, Judith; Barrera-Carmona, Cristina; Ponce-Martínez, Mayra; Gutiérrez-Hernández, Olga; Avilés-Salas, Alejandro; Cacho-Díaz, Bernardo.
Affiliation
  • Candelaria, Myrna; Instituto Nacional de Cancerología. Clinical Research Division. Mexico City. MX
  • Oñate-Ocaña, Luis F.; Instituto Nacional de Cancerología. Clinical Research Division. Mexico City. MX
  • Corona-Herrera, Judith; Instituto Nacional de Cancerología. Clinical Research Division. Mexico City. MX
  • Barrera-Carmona, Cristina; Instituto Nacional de Cancerología. Department of Hematology. Mexico City. MX
  • Ponce-Martínez, Mayra; Instituto Nacional de Cancerología. Clinical Research Division. Mexico City. MX
  • Gutiérrez-Hernández, Olga; Instituto Nacional de Cancerología. Clinical Research Division. Mexico City. MX
  • Avilés-Salas, Alejandro; Instituto Nacional de Cancerología. Department of Pathology. Mexico City. MX
  • Cacho-Díaz, Bernardo; Instituto Nacional de Cancerología. Department of Neuro-Oncology. Mexico City. MX
Rev. invest. clín ; 71(5): 349-358, Sep.-Oct. 2019. tab, graf
Article ي En | LILACS | ID: biblio-1289705
المكتبة المسؤولة: BR1.1
ABSTRACT
Background The outcome of patients with primary extranodal diffuse large B-cell lymphoma (PE-DLBCL) varies according to the primary site involved. Primary gastrointestinal, breast, bone, craniofacial, and testicular DLBCL are rare extranodal manifestations of DLBCL. Objective The objective of the study was to describe the clinical course of patients with PE-DLBCL disease in a referral cancer center. Results From 637 patients, 51 (8.77%) were considered as having PE-DLBCL (25 gastrointestinal, 12 craniofacial, 6 breast, 5 bone, and 3 with primary testicular DLBCL). Complete remission was higher in all PE-DLBCL sites (100% in testicular, 92.6% craniofacial, 83.3% breast, 80% bone, and 80% gastrointestinal) compared with 73.3% in nodal DLBCL. Although 2 cases with breast PE-DLBC relapsed, they achieved a complete response with chemotherapy. The overall survival at 5 years was 100%, 80%, 78%, 58%, 58%, and 62% for patients with primary breast, primary bone, gastrointestinal, primary craniofacial, primary testicular, and nodal DLBCL, respectively. Conclusions PE-DLBCLs constitute rare, primary sites of lymphoproliferative disorders in most cases, with localized disease and good prognosis. They require a combined chemoimmunotherapy with radiotherapy in most cases to improve local and systemic disease.
الموضوعات
Key words

النص الكامل: 1 الفهرس: LILACS الموضوع الرئيسي: Lymphoma, Large B-Cell, Diffuse / Immunotherapy / Lymph Nodes / Antineoplastic Agents نوع الدراسة: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies المحددات: Adult / Aged / Aged80 / Female / Humans / Male اللغة: En مجلة: Rev. invest. clín موضوع المجلة: MEDICINA السنة: 2019 نوع: Article

النص الكامل: 1 الفهرس: LILACS الموضوع الرئيسي: Lymphoma, Large B-Cell, Diffuse / Immunotherapy / Lymph Nodes / Antineoplastic Agents نوع الدراسة: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies المحددات: Adult / Aged / Aged80 / Female / Humans / Male اللغة: En مجلة: Rev. invest. clín موضوع المجلة: MEDICINA السنة: 2019 نوع: Article